Substituted N-Phenylpyrazine-2-carboxamides: synthesis and antimycobacterial evaluation
Language English Country Switzerland Media electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
19924056
PubMed Central
PMC6255326
DOI
10.3390/molecules14104180
PII: 14104180
Knihovny.cz E-resources
- MeSH
- Antitubercular Agents chemical synthesis chemistry pharmacology MeSH
- Mycobacterium avium drug effects MeSH
- Mycobacterium kansasii drug effects MeSH
- Mycobacterium tuberculosis drug effects MeSH
- Pyrazinamide chemistry MeSH
- Pyrazines chemical synthesis chemistry pharmacology MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 5-tert-butyl-6-chloro-N-(3-iodo-4-methyl-phenyl)pyrazine-2-carboxamide MeSH Browser
- Antitubercular Agents MeSH
- N-(3-iodo-4-methylphenyl)pyrazine-2-carboxamide MeSH Browser
- Pyrazinamide MeSH
- Pyrazines MeSH
The condensation of chlorides of substituted pyrazinecarboxylic acids with ringsubstituted anilines yielded twelve substituted pyrazinecarboxylic acid amides. The synthetic approach, analytical, and lipophilicity data of the newly synthesized compounds are presented. Two antituberculosis assays were used. Firstly, the antimycobacterial activity against four different Mycobacterium strains in a series of pyrazine derivatives was investigated. Secondly, the antimycobacterial evaluation was performed at the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) program. Interesting in vitro antimycobacterial activity was found, N-(3-iodo-4-methylphenyl) pyrazine-2-carboxamide (9) was most active derivative compound against M. tuberculosis (MIC < 2.0 micromol/L), while another iodo derivative 5-tert-butyl-6-chloro-N-(3-iodo-4-methyl-phenyl)pyrazine-2-carboxamide (12) was the most active compound in the TAACF antituberculosis screening program (IC(90) = 0.819 microg/mL).
See more in PubMed
Agrawal Y.K., Bhatt H.G., Raval H.G., Oza P.M., Vaidya H.B., Manna K., Gogoi P. Emerging trends in tuberculosis therapy—A review. J. Sci. Indust. Res. 2007;66:191–208.
Laughon B.E. New tuberculosis drugs in development. Curr. Topics Med. Chem. 2007;7:463–473. doi: 10.2174/156802607780059736. PubMed DOI
Doležal M. Biologically active pyrazines of natural and synthetic origin. Chem. Listy. 2006;100:959–966.
Speirs R.J., Welch J.T., Cynamon M.H. Activity of n-propyl pyrazinoate against pyrazinamide-resistant mycobacterium-tuberculosis: Investigation into mechanism of action and mechanism of resistence to pyrazinamide. Antimicrob. Agents Chemother. 1995;39:1269–1271. doi: 10.1128/AAC.39.6.1269. PubMed DOI PMC
Zhang Y., Wade M.M., Scorpio A., Zhang H., Sun Z.H. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 2003;52:790–795. doi: 10.1093/jac/dkg446. PubMed DOI
Ngo S.C., Zimhony O., Chung W.J., Sayahi H., Jacobs W.R., Welch J.T. Inhibition of isolated mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. Antimicrob. Agents Chemother. 2007;51:2430–2435. doi: 10.1128/AAC.01458-06. PubMed DOI PMC
Doležal M., Hartl J., Miletín M., Macháček M., Kráľová K. Synthesis and photosynthesis-inhibiting activity of some anilides of substituted pyrazine-2-carboxylic acids. Chem. Pap. 1999;53:126–128. doi: 10.1002/chin.199946161. DOI
Doležal M., Vičík R., Miletín M., Kráľová K. Synthesis and antimycobacterial, antifungal, and photosynthesis-inhibiting evaluation of some anilides of substituted pyrazine-2-carboxylic acids. Chem. Pap. 2000;54:245–248. doi: 10.1002/chin.200104176. DOI
Doležal M., Tůmová L., Kešetovičová D., Tůma J., Kráľová K. Substituted N-phenylpyrazine-2-carboxamides, their synthesis and evaluation as herbicides and abiotic elicitors. Molecules. 2007;12:2589–2598. doi: 10.3390/12122589. PubMed DOI PMC
Doležal M., Palek L., Vinšová J., Buchta V., Jampílek J., Kráľová K. Substituted pyrazinecarboxamides; synthesis and their biological evaluation. Molecules. 2006;11:242–256. doi: 10.3390/11040242. PubMed DOI PMC
Doležal M., Čmedlová P., Palek L., Vinšová J., Kuneš J., Buchta V., Jampílek J., Kráľová K. Synthesis and antimycobacterial evaluation of substituted pyrazinecarboxamides. Eur. J. Med. Chem. 2008;43:1105–1113. doi: 10.1016/j.ejmech.2007.07.013. PubMed DOI
Ancizu S., Moreno E., Torres E., Burguete A., Pérez-Silanes S., Benítez D., Villar R., Solano B., Marín A., Aldana I., Cerecetto H., González M., Monge A. Heterocyclic-2-carboxylic acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide derivatives as hits for the development of neglected disease drugs. Molecules. 2009;14:2256–2272. doi: 10.3390/molecules14062256. PubMed DOI PMC
Cynamon M.H., Speirs R.J., Welch J.T. In vitro antimycobacterial activity of 5-chloropyrazinamide. Antimicrob Agents Chemother. 1998;42:462–463. PubMed PMC
Wade M.M., Zhang Y. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J. Antimicrob. Chemother. 2006;58:936–941. doi: 10.1093/jac/dkl358. PubMed DOI
Abe Y., Shigeta Y., Uchimaru F., Okada S., Ozasayama E. Methyl 6-methoxypyrazine-2-carboxylate. JP Pat. 44012898. 1969 [Chem. Abstr. 1969, 71, 112979y.]
Doležal M., Hartl J., Lyčka A., Buchta V., Odlerová Ž. Synthesis and antituberculotic properties of some substituted pyrazinecarbothioamides. Collect. Czech. Chem. Commun. 1996;61:1102–1108. doi: 10.1135/cccc19961102. DOI
[accessed 27 August, 2009];TAACF. 2009 Available online: http://www.taacf.org/Process-text.htm#nhdp-text.